ORIGIN 3 Shows Two-Year Kidney-Function Preservation

Company Vera Therapeutics Event Type Phase III Final Analysis Modality TACI-Fc Fusion Protein (BAFF/APRIL Sequestration) Asset Atacicept-vymj (TRUTAKNA) Target BAFF and APRIL Disease Area Primary IgA Nephropathy Summary In the 428-patient final efficacy analysis of Phase III ORIGIN 3, atacicept-vymj preserved estimated glomerular filtration rate…